Boundless Bio (BOLD)

• Market cap: $25.7M
• 1 day: -0.86%
• 5 days: 0%
• 1 month: 2.68%
• 3 months: 5.5%
• 6 months: -32.35%
• Year to date: -57.88%
• 1 year: -64.17%
• 5 years: -91.93%
• 10 years: -91.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 64

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

19% less funds holding

Funds holding: 54 [Q1] → 44 (-10) [Q2]

32.38% less ownership

Funds ownership: 76.11% [Q1] → 43.72% (-32.38%) [Q2]

48% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 21

63% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 19

98% less capital invested

Capital invested by funds: $419M [Q1] → $9.88M (-$409M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4
• Avg. target: $4
• High target: $4

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell S. Kapoor

$4

Buy Maintained

11 Aug 2025